{"id":955568,"date":"2026-04-28T16:10:29","date_gmt":"2026-04-28T20:10:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/"},"modified":"2026-04-28T16:10:29","modified_gmt":"2026-04-28T20:10:29","slug":"trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/","title":{"rendered":"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026"},"content":{"rendered":"<h2>\nConference call and webcast to be held at 4:30 p.m. ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>NEW HAVEN, Conn., April  28, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3Q7Hkxg_IIM624FUByEvzGH5DcNiS3rYu9HDpGXC19NHANvy7PTaSAvydKApdfg9LP8PScAPahd4adwuS_evArTnqf8L9WS1ZWG0M4ylFliIvVw_EP38c25-Z-1AX_Kz\" rel=\"nofollow\" target=\"_blank\">Trevi Therapeutics, Inc.<\/a> (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company&#8217;s financial results for the quarter ended March 31, 2026.\u00a0<\/p>\n<p>\n        <strong>Conference Call and Webcast<\/strong><br \/>\n        <br \/>To register for the live conference call and webcast, please visit the \u2018Investors &amp; News\u2019 section of the Company\u2019s website or access directly at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t9NgBCIEm7SqIZ7tg2G-pHdcDvkOPhNGNOFVMxaJIjwCeF3mKbXGKPx9lKETU-wjUXphFuVRPWiRsVVcU67N7Oj9ny_cJ0vSEG42fhwywy8_z7H-10p8XF-R6JmEqORQcyBMgI_I_s0XTL5DjRUOU_7wdRqUOvDiPEsz8nWlu2w=\" rel=\"nofollow\" target=\"_blank\">ir.trevitherapeutics.com\/news-events\/events<\/a>. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company&#8217;s website following the event.<\/p>\n<p>\n        <strong>About Trevi Therapeutics, Inc.\u00a0<\/strong>\u00a0\u00a0\u00a0\u00a0<br \/>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.\u00a0<\/p>\n<p>Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients&#8217; quality of life.\u00a0 \u00a0\u00a0<\/p>\n<p>RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting &gt;8\u2005weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially. \u00a0\u00a0<\/p>\n<p>Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.\u00a0\u00a0<br \/>\u00a0\u00a0<br \/>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ujLwVbhNNYVqxgHgQhvrBAQyWw2zeVEDNFDMuS9lTAJZ1FINgmA8kMOkX4RrrME4-0etRsvK1EmJcUA3eoEVuNAKFF_Ag0y9TlgbCGdcsCWG52Be5_SbRKe3aNdNM9qi\" rel=\"nofollow\" target=\"_blank\"><u>www.TreviTherapeutics.com<\/u><\/a>\u00a0and follow Trevi on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CMD-M5KZRwptEk_F9-iqmxcagV-FrOopcYQooCAD3IqYV6OGB3D9v3Sqevn0oS5PY2XeNrYRur_V8LgFyXqd0g==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>\u00a0(formerly Twitter) and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wZxvpMIVoYUil6fa_UbPnQRUNgkLJGhxbG2Xw3yZF-DuzV1iyOUrPnz6I0_9Q9W1rbDauyhDYPRXvLCBjmPfDDUJtKK5LWemFHUn5QVN8P1U73l_bI6ewpjsdxM3c1tZ\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.\u00a0\u00a0<\/p>\n<p>\n        <strong>Investor Contact<\/strong>\u00a0\u00a0\u00a0<br \/>Jonathan Carlson\u00a0\u00a0\u00a0<br \/>Trevi Therapeutics, Inc.\u00a0\u00a0\u00a0<br \/>(203) 654 3286\u00a0\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JTpyX0YQS6cgOBMGlIwapHDSXJ_8SWAbUJX03ZrxGZac9Un9mjh8FLBerhmNefP5QVq_udnaQRKqGblDKOYzjw==\" rel=\"nofollow\" target=\"_blank\"><u>IR@trevitx.com<\/u><\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong>\u00a0\u00a0\u00a0<br \/>Rosalia Scampoli\u00a0\u00a0\u00a0<br \/>914-815-1465\u00a0\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_kRHCbt55d5XKy5hyx2MkNk4X5q2wmevhwX0nCZ05ZvwW0adKig6y3BuZo5CXOoc0wN9FEnzikg5zYVrD6uGnsSG7Xlv1nP6KY4NdZVdx6w5jUgODKR9Wo68peanPdTl\" rel=\"nofollow\" target=\"_blank\"><u>rscampoli@marketcompr.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTI5ZjQxZjctNzU5Mi00ZWFmLWI1OWItMWRlMmJiMGUzOTgxLTExMzY2ODctMjAyNi0wNC0yOC1lbg==\/tiny\/Trevi-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company&#8217;s financial results for the quarter ended March 31, 2026.\u00a0 Conference Call and Webcast To register for the live conference call and webcast, please visit the \u2018Investors &amp; News\u2019 section of the Company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955568","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company&#8217;s financial results for the quarter ended March 31, 2026.\u00a0 Conference Call and Webcast To register for the live conference call and webcast, please visit the \u2018Investors &amp; News\u2019 section of the Company\u2019s &hellip; Continue reading &quot;Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T20:10:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026\",\"datePublished\":\"2026-04-28T20:10:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/\"},\"wordCount\":552,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/\",\"name\":\"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=\",\"datePublished\":\"2026-04-28T20:10:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/","og_locale":"en_US","og_type":"article","og_title":"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - Market Newsdesk","og_description":"Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational\u00a0therapy\u00a0Haduvio\u2122\u00a0(oral nalbuphine ER)\u00a0for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD),\u00a0and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company&#8217;s financial results for the quarter ended March 31, 2026.\u00a0 Conference Call and Webcast To register for the live conference call and webcast, please visit the \u2018Investors &amp; News\u2019 section of the Company\u2019s &hellip; Continue reading \"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-28T20:10:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026","datePublished":"2026-04-28T20:10:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/"},"wordCount":552,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/","name":"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=","datePublished":"2026-04-28T20:10:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODU2MCM3NTcwMzU4IzIxMjUxMTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-5-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955568"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955568\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}